SEC Threatens Inspire With Civil Action
Inspire Pharmaceuticals Inc. disclosed Monday that it may face charges from the Securities and Exchange Commission over a Phase 3 clinical trial for its dry-eye product candidate, Prolacria....To view the full article, register now.
Already a subscriber? Click here to view full article